Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Warren Olanow"'
Autor:
Nicola L. Brice, Mark Carlton, David H. Margolin, Martin Bexon, Kim L. Matthews, Lee A. Dawson, Aaron L. Ellenbogen, C. Warren Olanow, Jordan Dubow, Karl Kieburtz
Publikováno v:
EClinicalMedicine, Vol 77, Iss , Pp 102882- (2024)
Summary: Background: CVN424 is a GPR6 inverse agonist that provides selective pharmacological control of the indirect striatopallidal pathway. We assessed the safety and efficacy of CVN424 as an adjunctive treatment to levodopa for reducing OFF-time
Externí odkaz:
https://doaj.org/article/03ffbbb6c9d240da9bd6c36037040312
Autor:
Peter LeWitt, Grace S. Liang, C. Warren Olanow, Karl D. Kieburtz, Roland Jimenez, Kurt Olson, Olga Klepitskaya, Gordon Loewen
Publikováno v:
Clinical Neuropharmacology. 46:43-50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc4165c9891248c920def75af68f1b31
https://doi.org/10.1097/wnf.0000000000000538
https://doi.org/10.1097/wnf.0000000000000538
Autor:
Fabrizio, Stocchi, Elizabeth L, Peckham, Maria Francesca, De Pandis, Ken, Sciarappa, Robert, Kleiman, Felix, Agbo, C Warren, Olanow, David, Blum, Bradford, Navia
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1068-1077
A randomized thorough QT study was conducted to assess the effects of apomorphine sublingual film (SL-APO) on corrected QT interval (QTc) and other cardiac conduction parameters in patients with Parkinson's disease (PD) and "OFF" episodes. Patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fb20264c7fe1801c394d853dce3db9c
https://doi.org/10.1002/cpdd.1147
https://doi.org/10.1002/cpdd.1147
Autor:
Nissim Sasson, Shir Fuchs Orenbach, Nir Giladi, Sheila Oren, David Arkadir, Tanya Simuni, Peter A. LeWitt, Abraham Zlotogorski, Alberto J. Espay, Werner Poewe, Astrid Thomas, Karl Kieburtz, Stuart Isaacson, Georg Ebersbach, Tami Yardeni, C Warren Olanow, Liat Adar, Ryan Case, Olivia Rosenfeld, Fabrizio Stocchi, Aaron Ellenbogen
Publikováno v:
Movement Disorders. 36:2687-2692
Background Continuous, subcutaneous (SC) levodopa/carbidopa infusion with ND0612 is under development as a treatment for patients with Parkinson's disease (PD) and motor fluctuations. Objective Evaluate 1-year safety data. Methods BeyoND is an open-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68a00bacc2997d5b31a70dc6f2f9c4e3
https://doi.org/10.1002/mds.28758
https://doi.org/10.1002/mds.28758
Autor:
Shir Fuchs Orenbach, Werner Poewe, Ryan Case, Sheila Oren, Fabrizio Stocchi, Aaron Ellenbogen, Tami Yardeni, Alberto J. Espay, Liat Adar, Mika Leinonen, C. Warren Olanow
Publikováno v:
Journal of Parkinson's Disease
Background: ND0612 is a continuous, subcutaneous levodopa/carbidopa delivery system in development for patients with Parkinson’s disease (PD) experiencing motor fluctuations Objective: Evaluate the efficacy and safety of two ND0612 dosing regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bc344a714dac14a6a201e6e49579834
http://europepmc.org/articles/PMC7990424
http://europepmc.org/articles/PMC7990424
Autor:
Michal Geva, Karl Kieburtz, Andrew McGarry, Mika Leinonen, Michael R. Hayden, C. Warren Olanow
Publikováno v:
Journal of Huntington's Disease
Background: No pharmacological treatment has been demonstrated to provide a functional benefit for persons with Huntington’s disease (HD). Pridopidine is a sigma-1-receptor agonist shown to have beneficial effects in preclinical models of HD. Objec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3c11384e608a711f1801f09f6f7bd9
http://europepmc.org/articles/PMC7836066
http://europepmc.org/articles/PMC7836066
Publikováno v:
Movement Disorders. 35:1055-1061
Background Extensive scientific and clinical evidence indicates that continuous delivery of a dopaminergic agent is associated with significant reduction in motor complications compared with intermittent oral dosing with the same agent. There has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d2ec7e909f9f9a3fa58873de06f5dc
https://doi.org/10.1002/mds.28027
https://doi.org/10.1002/mds.28027
Publikováno v:
Brain
Chu et al. present findings from post-mortem assessment of two individuals with advanced Parkinson’s disease who received gene therapy with the trophic factor neurturin, 8 and 10 years prior to death. The cases represent the longest survival times
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075ffdd1205abbbc2a7d6e9159ab43e9
http://europepmc.org/articles/PMC7089653
http://europepmc.org/articles/PMC7089653
Publikováno v:
Neurobiology of Disease, Vol 35, Iss 3, Pp 385-398 (2009)
We explored the relationship between ubiquitin proteasome system (UPS) and lysosomal markers and the formation of α-synuclein (α-syn) inclusions in nigral neurons in Parkinson disease (PD). Lysosome Associated Membrane Protein 1(LAMP1), Cathepsin D
Externí odkaz:
https://doaj.org/article/bf3d20edf888427bb99553cb6bcc75d6
Autor:
C. Warren Olanow, Milton H. Werner
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 37(1)
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease of the central nervous system, with an estimated 5 000 000 cases worldwide. Historically characterized by the progressive loss of dopaminergic neurons in the substantia n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e8ce889e58d29ef8d497eb873f24f1
https://pubmed.ncbi.nlm.nih.gov/34816484
https://pubmed.ncbi.nlm.nih.gov/34816484